ReviewInternational journal of molecular sciences2024
Interplay Between Ocular Ischemia and Glaucoma: An Update.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Nanoformulations for Ocular Drug Delivery in Glaucoma: From Metal-Based Nanoparticles to Advanced Nanocarriers.Pharmaceutics · 2026Review
- The Dual Role of Macroglia in Glaucoma: Deciphering the Contributions of Astrocytes and Müller Cells to Retinal Neurodegeneration and Neuroprotection.International journal of molecular sciences · 2026Review
- Carotid intima-media thickness in relation to primary open-angle glaucoma: epidemiological and structural evidence from a cross-sectional study.BMJ open ophthalmology · 2026Article
- Ischemia-Induced Neurodegeneration in Glaucoma: Mechanistic Insights and Translational Opportunities for Psychoplastogen-Based Therapies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Complications of minimally invasive surgery for primary open-angle glaucoma in patients with diabetic retinopathy: a retrospective cohort study.International ophthalmology · 2026Article
- An Exploratory Study of Six-Month Niacinamide Supplementation on Macular Structure and Electrophysiology in Primary Open-Angle Glaucoma.Vision (Basel, Switzerland) · 2026Article
- Ferroptosis in retinal neurodegeneration: mechanistic vulnerability, therapeutic targeting, and translational barriers.Frontiers in medicine · 2026Review
- Electroacupuncture as an adjunctive therapy for drug-refractory primary open-angle glaucoma: a CARE-compliant case report.Frontiers in medicine · 2026Article
- Gasotransmitters in Glaucoma: A New Paradigm.Bulletin of pharmaceutical research · 2026Article
- Relationship Between Macular Perfusion Density and Central Visual Field Loss in Primary Open Angle Glaucoma.Journal of glaucoma · 2026Article
- Epigenetics of glaucoma in the trabecular meshwork.Clinical epigenetics · 2025Review
- Longitudinal quantitative assessment of macular retinal and choroidal remodeling after trabeculectomy in chronic primary angle-closure glaucoma using ultra-widefield SS-OCTA.Scientific reports · 2025Observational
- Changes in Quality of Life Among Glaucoma Patients Following Six Months of Niacinamide Supplementation.Nutrients · 2025Article
- The Endocannabinoid System in Retinal Müller Glia: Lessons From Astrocyte Research.Neurochemical research · 2025Review
- Lights and Shadows on Artificial Intelligence in Glaucoma: Transforming Screening, Monitoring, and Prognosis.Journal of clinical medicine · 2025Review
- Sunitinib's Effect on Bilateral Optic Nerve Damage in Rats Following the Unilateral Clamping and Unclamping of the Common Carotid Artery.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is a main cause of irreversible blindness worldwide, with a high impact on productivity and quality of life. The mechanical and ischemic theories are currently the most recognized pathophysiological pathways that explain the neurodegeneration of retinal nerve fibers in glaucoma. In this narrative review, aspects of ischemia in glaucoma are discussed, including vascular dysregulation, retinal ischemia signaling pathways, roles of vascular endothelial growth factors, and future research and therapeutic directions. In conclusion, a better understanding of the ischemic processes in glaucoma may lead to innovative treatment options and improved management and follow-up of our patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.